Acute Myeloid Leukemia

Acute Myeloid Leukemia and Acute Complications Brad Clifford 10/29/08 and 10/31/08

Objectives ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Hematologic Malignancies ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Acute Myeloid Leukemia ,[object Object],[object Object],[object Object],[object Object]

Myelopoiesis ,[object Object],[object Object],[object Object],[object Object]

Epidemiology ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Epidemiology ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Clinical symptoms ,[object Object],[object Object],[object Object],[object Object]

Clinical symptoms ,[object Object],[object Object]

Physical Findings ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Gingival Infiltration in Monocytic (AML M4 eos) Variant of AML ,[object Object]

Clinical symptoms/Physical Findings ,[object Object],[object Object]

Diagnosis ,[object Object],[object Object],[object Object],[object Object],[object Object]

FAB Classification of AML ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

WHO Classification ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

AML M3 (Promyelocytic) ,[object Object]

Case #1 ,[object Object],[object Object],[object Object],[object Object],[object Object]

Leukostasis ,[object Object],[object Object],[object Object],[object Object]

Leukostasis in AML ,[object Object]

Leukostasis ,[object Object],[object Object],[object Object],[object Object],[object Object]

Leukapheresis ,[object Object],[object Object],[object Object],[object Object]

Leukapheresis ,[object Object],[object Object],[object Object]

Tumor Lysis Syndrome ,[object Object],[object Object]

Tumor Lysis Syndrome ,[object Object],[object Object],[object Object],[object Object],[object Object]

Tumor Lysis Syndrome ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

DIC (Disseminated Intravascular Coagulation) ,[object Object],[object Object],[object Object],[object Object]

Coagulation cascade ,[object Object]

DIC ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

DIC ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Treatment of DIC ,[object Object],[object Object],[object Object],[object Object]

DIC ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

CNS Involvement ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

CNS Involvement ,[object Object],[object Object],[object Object],[object Object],[object Object]

Ocular Involvement ,[object Object],[object Object],[object Object],[object Object]

Other Complications ,[object Object],[object Object],[object Object]

Treatment of AML ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Treatment ,[object Object],[object Object],[object Object]

Prognostic Factors in AML ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Treatment ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Disease Free Survival (EORTC/GIMEMA trial) ,[object Object]

Overall Survival (EORTC/GIMEMA trial) ,[object Object]

Treatment ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Survival in AML ,[object Object]

Treatment in Refractory or Relapsed AML ,[object Object],[object Object],[object Object],[object Object],[object Object]

Future Therapeutic Targets ,[object Object],[object Object],[object Object],[object Object]

Resources ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Acute Myeloid Leukemia

Recomendados

Recomendados

Mais conteúdo relacionado

Mais procurados

Mais procurados (20)

Destaque

Destaque (7)

Semelhante a Acute Myeloid Leukemia

Semelhante a Acute Myeloid Leukemia (20)

Último

Último (20)

Acute Myeloid Leukemia